NAFLD is the Leading Cause of Donor Rejection in Living Donor Liver Transplantation

Kotecha, Hardik; Saraf, Neeraj; Saigal, Sanjiv; Choudhary, Narendra S.; Yadav, Amardeep; Mohanka, Ravi; Rastogi, Amit; Menon, P.B.; Goja, Sanjay; Soin, Arvinder S.

doi:10.1016/j.jceh.2013.03.007

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with the metabolic syndrome may have progressive liver disease, even with the apparent benign initial biopsy [56][57][58]. NAFLD is the leading cause of donor rejection in the living donor liver transplantation [59]. Experience from liver transplantation centres shows that steatosis [30 % in the donor liver is associated with a higher risk of primary non-function and graft initial poor function, as compared to grafts with no or\30 % steatosis [60].…”

Section: Fatty Livermentioning

confidence: 99%

Pattern and profile of chronic liver disease in acute on chronic liver failure

Abbas

Shazi²

2015

Hepatol Int

View full text Add to dashboard Cite

The etiology of the chronic liver disease (CLD) in patients with acute on chronic liver failure (ACLF) may vary from region to region. The major cause of underlying CLD is viral (hepatitis B and C) in the East, while it is alcohol related in the West and in some parts of the Indian subcontinent. Autoimmune liver disease and Wilson's disease are the major underlying etiologies in the pediatric age group. The patients with CLD without cirrhosis should be included when defining ACLF. Non-alcoholic fatty liver disease related chronic liver insult in patients with known risk factors for progressive disease should be taken as a chronic liver disease in the setting of ACLF, whereas fatty liver with normal aminotransferases in low risk patients should not. The patients with CLD and previous decompensation should be excluded. Diagnosis of chronic liver disease in the setting of ACLF is made by history, physical examination and previously available or recent laboratory, endoscopic or radiological investigations. A liver biopsy through the transjugular route may help in cases where the presence of underlying CLD or its cause is not clear. The need of liver biopsy in ACLF should, however, be individualized. Standardization of liver biopsy assessment is essential for a uniform approach to the diagnosis and treatment of CLD and acute insult. Tools to measure liver stiffness may aid in identifying patients with advanced fibrosis. Studies are needed to validate the performance of these tests in the setting of ACLF.

show abstract

Section: Fatty Livermentioning

confidence: 99%

Pattern and profile of chronic liver disease in acute on chronic liver failure

Abbas

Shazi²

2015

Hepatol Int

View full text Add to dashboard Cite

show abstract

“…1,2 In addition NAFLD is leading cause of donor rejection in living donor liver transplantation program at our centre. 3 Achievement and maintenance of weight loss is difficult in clinical practice. Data on effect of weight loss on liver histology in NAFLD patients has come from either clinical trials which achieve weight loss on a long term or from studies of bariatric surgery patients.…”

mentioning

confidence: 99%

Rapid Reversal of Liver Steatosis With Life Style Modification in Highly Motivated Liver Donors

Choudhary

Saraf

Saigal

et al. 2015

Journal of Clinical and Experimental Hepatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Livers with 30%-60% fat have poor results, with decreased graft survival and decreased patient survival[ 109 ]. Moreover, hepatic steatosis is reported to be a leading cause of donor rejection in LDLT[ 110 ]. In some transplantation centers, approximately 40% of donor grafts are discarded because of severe liver steatosis[ 9 ].…”

Section: Liver Graft Steatosismentioning

confidence: 99%

Feasibility of using marginal liver grafts in living donor liver transplantation

Xiang

Zhang

et al. 2018

WJG

View full text Add to dashboard Cite

Liver transplantation (LT) is one of the most effective treatments for end-stage liver disease caused by related risk factors when liver resection is contraindicated. Additionally, despite the decrease in the prevalence of hepatitis B virus (HBV) over the past two decades, the absolute number of HBsAg-positive people has increased, leading to an increase in HBV-related liver cirrhosis and hepatocellular carcinoma. Consequently, a large demand exists for LT. While the wait time for patients on the donor list is, to some degree, shorter due to the development of living donor liver transplantation (LDLT), there is still a shortage of liver grafts. Furthermore, recipients often suffer from emergent conditions, such as liver dysfunction or even hepatic encephalopathy, which can lead to a limited choice in grafts. To expand the pool of available liver grafts, one option is the use of organs that were previously considered “unusable” by many, which are often labeled “marginal” organs. Many previous studies have reported on the possibilities of using marginal grafts in orthotopic LT; however, there is still a lack of discussion on this topic, especially regarding the feasibility of using marginal grafts in LDLT. Therefore, the present review aimed to summarize the feasibility of using marginal liver grafts for LDLT and discuss the possibility of expanding the application of these grafts.

show abstract

NAFLD is the Leading Cause of Donor Rejection in Living Donor Liver Transplantation

Cited by 4 publications

References 0 publications

Pattern and profile of chronic liver disease in acute on chronic liver failure

Pattern and profile of chronic liver disease in acute on chronic liver failure

Rapid Reversal of Liver Steatosis With Life Style Modification in Highly Motivated Liver Donors

Feasibility of using marginal liver grafts in living donor liver transplantation

Contact Info

Product

Resources

About